MapLight completes enrollment in Phase 2 ZEPHYR schizophrenia trial for ML-007C-MA

MapLight Therapeutics, Inc.

MapLight Therapeutics, Inc.

MPLT

0.00
  • MapLight Therapeutics completed enrollment in ZEPHYR Phase 2 trial of ML-007C-MA for schizophrenia, positioning program for near-term data readout.
  • Topline results have not been presented; data from ZEPHYR expected by mid-August 2026.
  • Separate IRIS Phase 2 trial of ML-004 in autism spectrum disorder finished final patient visit, moving study into analysis phase.
  • IRIS topline results also scheduled for mid-August 2026, setting up a dual Phase 2 catalyst for MapLight.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief on May 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.